Dr. Pranitha Vbr Prodduturvar, MD

Dr. Prodduturvar practices at Northside Hospital Atlanta in Atlanta, Georgia, part of Northside Hospital.

Dr. Prodduturvar's NPI, 1114183902, was assigned on August 1, 2008. Dr. Prodduturvar holds Alabama license MD.37066.

Dr. Prodduturvar's primary practice is Northside Hospital Atlanta, at 1000 Johnson Ferry Road, NE, Atlanta, GA 30342 in Fulton County. The practice phone is (404) 851-8000.

Dr. Prodduturvar's primary practice is Northside Hospital Atlanta in Atlanta, Georgia, part of Northside Hospital. Dr. Prodduturvar is also affiliated with Northside Hospital Forsyth. The medical group on file is Atlanta Cancer Care. Dmand AI also links Dr. Prodduturvar to 2 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Prodduturvar practices, 5 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Prodduturvar's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dmand AI has Dr. Prodduturvar's licenses on file in 4 states: Alabama, Georgia, Minnesota and Nebraska.

CMS data shows 290 Medicare services from Dr. Prodduturvar across 6 procedure codes in 2024, for 103 Medicare patients. Medicare paid $22,545 for them.

CMS counts 103 Medicare patients who saw Dr. Prodduturvar in 2024. The largest group is 65 to 74, with 46 patients. 75% of them have high blood pressure, and 70% have high cholesterol. 21% are also on Medicaid. Their average risk score is 2.59, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Prodduturvar's median patient age at 61, with 69% women.

In 2024, Dr. Prodduturvar wrote 376 Medicare Part D claims for 94 patients. 80% of them were for generic drugs. CMS names the drug for 222 of them, across 11 drugs with 11 or more claims each, at $531,841 in total drug cost. In 2023, CMS named 255 claims across 13 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Prodduturvar for performance year 2024, reported as part of a group. Dr. Prodduturvar accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 584 general payments to Dr. Prodduturvar from 63 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 53% of the total. Bristol-Myers Squibb Company paid the most, $24,003.